Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bubs Australia Ltd. ( (AU:BUB) ) just unveiled an announcement.
Bubs Australia Limited reported a 30% increase in net revenue to $25.6 million for Q1 FY26, with a gross profit margin of 46.4% and a positive EBITDA of $0.5 million. Despite challenges in inventory and cash flow, particularly in the USA, the company is optimistic about meeting customer demand and achieving growth targets. The USA market showed strong performance, although other regions like China and Australia experienced revenue declines. The company is actively managing inventory issues and expects improvements by the end of the current quarter. Bubs is also awaiting FDA approval for its products by the end of 2025, which could further enhance its market position.
The most recent analyst rating on (AU:BUB) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
More about Bubs Australia Ltd.
Founded in 2006 in Australia, Bubs Australia Limited focuses on providing clean nutrition through its range of infant formulas and baby food products. The company offers Bubs A2 Beta-Casein Protein, Bubs Organic Grass-fed, and Easy-Digest Goat Milk Infant Formula, along with a variety of organic baby foods. Bubs’ products are available in major supermarkets and pharmacies across Australia and are exported to markets in China, Southeast Asia, the Middle East, and the USA.
Average Trading Volume: 1,919,848
Technical Sentiment Signal: Hold
Current Market Cap: A$147.5M
For a thorough assessment of BUB stock, go to TipRanks’ Stock Analysis page.